# Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

> **NCT06030622** · PHASE1,PHASE2 · UNKNOWN · sponsor: **State University of New York - Downstate Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)
- **DRUG:** C3 (Metformin, Simvastatin, and Digoxin) only

## Key facts

- **NCT ID:** NCT06030622
- **Lead sponsor:** State University of New York - Downstate Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-17
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030622, "Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06030622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*